You are here: Home » Companies » News
Business Standard

Abbott to increase India investment, R&D spend

India is one of the fast growing markets for Abbott and the company is present in four business segments here

BS Reporter  |  Mumbai 

Abbot

Abbott will increase its investment in research and development and expand its manufacturing plants in India to cater to domestic market and exports, the healthcare company announced today. It however did not disclose the sum.

"India is one of the most important places in the world for Abbott, and we are investing here accordingly," said Miles D White, chairman and CEO of US headquartered Abbott. "We intend to be a strong, committed, and contributing part of India's future," he added.

India is one of the fast growing markets for Abbott and the company is present in four business segments - medical devices, diagnostics, nutritional products and branded generic pharmaceuticals.

The company said it will increase its infrastructure, capabilities and staff at both its pharmaceutical and nutrition R&D facilities to drive innovations and new product introductions in India. It will also increase local sourcing for its nutritional products business and is supporting dairy farmers for the purpose.

Pharmaceutical development and manufacturing facilities in Mumbai and Baddi in Himachal Pradesh are being expanded to meet growing needs in India and also export branded generic pharmaceuticals to other emerging markets in Southeast Asia and Africa," the company said in a statement.

Dear Reader,


Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

First Published: Wed, September 30 2015. 19:00 IST
RECOMMENDED FOR YOU
.